Onapristone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Onapristone
Accession Number
DB12637
Type
Small Molecule
Groups
Investigational
Description

Onapristone has been used in trials studying the treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy.

Structure
Thumb
Synonyms
Not Available
External IDs
ZK-98299
Categories
UNII
H6H7G23O3N
CAS number
96346-61-1
Weight
Average: 449.635
Monoisotopic: 449.29299412
Chemical Formula
C29H39NO3
InChI Key
IEXUMDBQLIVNHZ-YOUGDJEHSA-N
InChI
InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
IUPAC Name
(10S,11S,14S,15R,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-14-(3-hydroxypropyl)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one
SMILES
CN(C)C1=CC=C(C=C1)[[email protected]]1C[[email protected]]2(C)[[email protected]@H](CC[[email protected]]2(O)CCCO)[[email protected]@H]2CCC3=CC(=O)CCC3=C12

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UGlucocorticoid receptorNot AvailableHuman
UProbable G-protein coupled receptor 133Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Onapristone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Onapristone.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Onapristone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Onapristone.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Onapristone.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Onapristone.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Onapristone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Onapristone.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Onapristone.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Onapristone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Onapristone.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Onapristone.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Onapristone.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Onapristone.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Onapristone.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Onapristone.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Onapristone.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Onapristone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Onapristone.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Onapristone.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5311505
PubChem Substance
347828846
ChemSpider
4470982
BindingDB
50366558
ChEMBL
CHEMBL1908373

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentAndrogen-independent Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Cancer / Recurrent Prostate Cancer1
1, 2RecruitingTreatmentProgesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00759 mg/mLALOGPS
logP4.63ALOGPS
logP3.96ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)14.34ChemAxon
pKa (Strongest Basic)4.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area60.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity135.3 m3·mol-1ChemAxon
Polarizability52.99 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Oxosteroids
Direct Parent
Oxosteroids
Alternative Parents
3-oxosteroids / 17-hydroxysteroids / Dialkylarylamines / Aniline and substituted anilines / Cyclohexenones / Tertiary alcohols / Cyclic alcohols and derivatives / Primary alcohols / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
3-oxosteroid / Hydroxysteroid / Oxosteroid / 17-hydroxysteroid / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Cyclohexenone / Monocyclic benzene moiety / Benzenoid
show 17 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Schaaf MJ, Lewis-Tuffin LJ, Cidlowski JA: Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility. Mol Endocrinol. 2005 Jun;19(6):1501-15. Epub 2005 Feb 10. [PubMed:15705660]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled receptor activity
Specific Function
Orphan receptor. Signals via G(s)-alpha family of G-proteins.
Gene Name
ADGRD1
Uniprot ID
Q6QNK2
Uniprot Name
Adhesion G-protein coupled receptor D1
Molecular Weight
96529.025 Da
References
  1. Sachdeva G, Gadkar S, Shah CA, Kholkute SD, Puri CP: Characterization of a critical region in the hormone binding domain of sperm progesterone receptor. Int J Androl. 2005 Apr;28(2):120-4. [PubMed:15811074]

Drug created on October 20, 2016 17:22 / Updated on November 09, 2017 05:10